Resumen de A New Monoclonal Antibody for Ulcerative Colitis and Crohn's Disease

Diane S. Aschenbrenner

• * Vedolizumab (Entyvio) is a newly approved treatment for adults with moderate-to-severe ulcerative colitis or moderate-to-severe Crohn's disease when standard therapies haven't been successful.

  * The most common adverse effects are nasopharyngitis, headache, joint pain, nausea, and fever. Vedolizumab can also produce hypersensitivity (anaphylactic) and infusion-related reactions, hepatotoxicity, and progressive multifocal leukoencephalopathy.